ZBH · Zimmer Biomet Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.09B | - | $2.00B | $2.08B | $1.91B | - | $1.82B | $1.94B | $1.89B | - |
| Cost of Revenue | $576.20M | - | $559.30M | $592.20M | $549.80M | - | $538.60M | $553.60M | $512.30M | - |
| Gross Profit | $1.51B | - | $1.44B | $1.49B | $1.36B | - | $1.29B | $1.39B | $1.38B | - |
| R&D | $103.40M | - | $115.90M | $113.30M | $110.60M | - | $111.60M | $109.40M | $107.90M | - |
| SG&A | $849.90M | - | $811.40M | $814.80M | $758.80M | - | $709.70M | $737.10M | $736.20M | - |
| Total Operating Expenses | $1.71B | - | $1.65B | $1.78B | $1.62B | - | $1.54B | $1.59B | $1.62B | - |
| D&A | $270.00M | - | $250.90M | $271.80M | $254.40M | - | - | - | $238.60M | - |
| Operating Income | $373.20M | - | $351.30M | $300.00M | $292.30M | - | $279.50M | $351.30M | $265.90M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $63.00M | - | $48.00M | $71.20M | $46.50M | - | ($18.90M) | $59.10M | $42.30M | - |
| Net Income | $238.10M | - | $230.90M | $152.80M | $182.00M | - | $249.10M | $242.80M | $172.40M | - |
| EPS - Basic | $1.22 | - | $1.17 | $0.77 | $0.92 | - | $1.23 | $1.18 | $0.84 | - |
| EPS - Diluted | $1.22 | - | $1.16 | $0.77 | $0.91 | - | $1.23 | $1.18 | $0.84 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $424.20M | $591.90M | $1.29B | $556.90M | $1.38B | $525.50M | $569.00M | $420.10M | $393.00M | $415.80M |
| Accounts Receivable | $1.73B | $1.70B | $1.60B | $1.61B | $1.53B | $1.48B | $1.48B | $1.42B | $1.45B | $1.44B |
| Inventory | $2.25B | $2.29B | $2.48B | $2.45B | $2.24B | $2.24B | $2.37B | $2.37B | $2.39B | $2.39B |
| Accounts Payable | $361.20M | $303.00M | $315.30M | $348.70M | $301.30M | $194.60M | $322.40M | $341.80M | $370.30M | $410.60M |
| Current Assets | $4.96B | $5.12B | $5.83B | $5.05B | $5.59B | $4.67B | $4.86B | $4.64B | $4.63B | $4.61B |
| Total Assets | $22.72B | $23.09B | $23.49B | $22.87B | $22.18B | $21.37B | $21.72B | $21.52B | $21.45B | $21.50B |
| Current Liabilities | $2.86B | $2.58B | $2.40B | $2.70B | $2.29B | $2.45B | $3.57B | $3.61B | $2.80B | $2.86B |
| Long-term Debt | $6.30B | $6.93B | $7.51B | $6.75B | $6.58B | $5.34B | $4.74B | $3.96B | $4.83B | $4.87B |
| Total Liabilities | $10.04B | $10.39B | $10.72B | $10.33B | $9.78B | $8.89B | $9.34B | $8.77B | $8.85B | $9.01B |
| Stockholders' Equity | $12.67B | $12.70B | $12.76B | $12.53B | $12.40B | $12.47B | $12.37B | $12.74B | $12.60B | $12.48B |
| Retained Earnings | $11.80B | $11.61B | $11.52B | $11.34B | $11.23B | $11.10B | $10.90B | $10.70B | $10.51B | $10.38B |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $359.40M | - | - | - | $382.80M | - | - | - | $228.00M | - |
| Investing Cash Flow | ($159.00M) | - | - | - | ($106.00M) | - | - | - | ($195.00M) | - |
| Financing Cash Flow | ($369.20M) | - | - | - | $575.40M | - | - | - | ($50.10M) | - |
| CapEx | $36.30M | - | - | - | $44.60M | - | - | - | $55.10M | - |
| Free Cash Flow | $323.10M | - | - | - | $338.20M | - | - | - | $172.90M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 72.4% | - | 72.1% | 71.5% | 71.2% | - | 70.5% | 71.5% | 72.9% | - |
| Operating margin | 17.9% | - | 17.6% | 14.4% | 15.3% | - | 15.3% | 18.1% | 14.1% | - |
| EBITDA margin | 30.8% | - | 30.1% | 27.5% | 28.6% | - | - | - | 26.7% | - |
| Net margin | 11.4% | - | 11.5% | 7.4% | 9.5% | - | 13.7% | 12.5% | 9.1% | - |
| Free cash flow margin | 15.5% | - | - | - | 17.7% | - | - | - | 9.2% | - |
| FCF / Net income | 1.36 | - | - | - | 1.86 | - | - | - | 1.00 | - |
| R&D / Revenue | 5.0% | - | 5.8% | 5.5% | 5.8% | - | 6.1% | 5.6% | 5.7% | - |
| SG&A / Revenue | 40.7% | - | 40.5% | 39.2% | 39.7% | - | 38.9% | 38.0% | 39.0% | - |
| Effective tax rate | 20.9% | - | 17.2% | 31.8% | 20.4% | - | -8.2% | 19.6% | 19.7% | - |
| Return on assets | 1.0% | - | 1.0% | 0.7% | 0.8% | - | 1.1% | 1.1% | 0.8% | - |
| Return on equity | 1.9% | - | 1.8% | 1.2% | 1.5% | - | 2.0% | 1.9% | 1.4% | - |
| Return on invested capital | 1.6% | - | 1.4% | 1.1% | 1.2% | - | 1.6% | 1.7% | 1.2% | - |
| Liquidity | ||||||||||
| Current ratio | 1.73 | 1.98 | 2.43 | 1.87 | 2.44 | 1.91 | 1.36 | 1.29 | 1.66 | 1.61 |
| Quick ratio | 0.95 | 1.10 | 1.39 | 0.96 | 1.46 | 0.99 | 0.70 | 0.63 | 0.80 | 0.78 |
| Cash ratio | 0.15 | 0.23 | 0.54 | 0.21 | 0.60 | 0.21 | 0.16 | 0.12 | 0.14 | 0.15 |
| Leverage | ||||||||||
| Debt / Equity | 0.50 | 0.55 | 0.59 | 0.54 | 0.53 | 0.43 | 0.38 | 0.31 | 0.38 | 0.39 |
| Debt / Assets | 0.28 | 0.30 | 0.32 | 0.30 | 0.30 | 0.25 | 0.22 | 0.18 | 0.22 | 0.23 |
| Debt / EBITDA | 9.79 | - | 12.48 | 11.81 | 12.03 | - | - | - | 9.57 | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.79 | 1.82 | 1.84 | 1.83 | 1.79 | 1.71 | 1.76 | 1.69 | 1.70 | 1.72 |
| Liabilities / Assets | 0.44 | 0.45 | 0.46 | 0.45 | 0.44 | 0.42 | 0.43 | 0.41 | 0.41 | 0.42 |
| Efficiency | ||||||||||
| Asset turnover | 0.09 | - | 0.09 | 0.09 | 0.09 | - | 0.08 | 0.09 | 0.09 | - |
| Inventory turnover | 0.26 | - | 0.23 | 0.24 | 0.24 | - | 0.23 | 0.23 | 0.21 | - |
| Days sales outstanding | 302d | - | 291d | 283d | 293d | - | 296d | 267d | 279d | - |
| Days inventory outstanding | 1423d | - | 1621d | 1513d | 1490d | - | 1605d | 1563d | 1702d | - |
| Days payable outstanding | 229d | - | 206d | 215d | 200d | - | 218d | 225d | 264d | - |
| Cash conversion cycle | 1497d | - | 1707d | 1581d | 1583d | - | 1683d | 1604d | 1717d | - |
| Valuation | ||||||||||
| P / E | 74.1x | - | 84.9x | 118.5x | 124.4x | - | 87.8x | 92.0x | 157.1x | - |
| P / B | 1.4x | - | 1.5x | 1.4x | 1.8x | - | 1.8x | 1.8x | 2.2x | - |
| P / S | 8.5x | - | 9.8x | 8.7x | 11.8x | - | 12.0x | 11.5x | 14.4x | - |
| EV / EBITDA | 36.7x | - | 42.8x | 42.5x | 50.8x | - | - | - | 62.7x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 9.3% | - | 9.7% | 7.0% | 1.1% | - | 4.0% | 3.9% | 3.2% | - |
| Revenue CAGR (3y) | 4.5% | - | 6.2% | 5.2% | 4.7% | - | -1.8% | -1.4% | 0.7% | - |
| Revenue CAGR (5y) | 2.5% | - | 0.7% | 11.1% | 1.4% | - | -0.7% | -0.5% | -0.9% | - |
| Gross profit growth (YoY) | 11.1% | - | 12.2% | 7.0% | -1.3% | - | 4.1% | 3.3% | 3.5% | - |
| Operating income growth (YoY) | 27.7% | - | 25.7% | -14.6% | 9.9% | - | 4.8% | 6.6% | -18.8% | - |
| Net income growth (YoY) | 30.8% | - | -7.3% | -37.1% | 5.6% | - | 53.1% | 15.8% | -25.8% | - |
| EPS growth (YoY) | 34.1% | - | -5.7% | -34.7% | 8.3% | - | 59.7% | 18.0% | -24.3% | - |
| EPS CAGR (3y) | 3.2% | - | 8.0% | 1.8% | 135.1% | - | 21.3% | 20.8% | -3.7% | - |
| EPS CAGR (5y) | 5.4% | - | 0.0% | - | - | - | -10.0% | 12.7% | -6.9% | - |
| FCF growth (YoY) | -4.5% | - | - | - | 95.6% | - | - | - | -33.8% | - |
| FCF CAGR (5y) | 8.1% | - | - | - | -3.8% | - | - | - | -6.8% | - |
| Book value growth (YoY) | 2.2% | 1.8% | 3.1% | -1.7% | -1.6% | -0.1% | -1.1% | 3.0% | 3.7% | 3.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$8.23B totalKnees$3.32B · 40.4%
SET$2.15B · 26.1%
Hips$2.09B · 25.4%
Technology And Data Bone Cement And Surgical$665.60M · 8.1%
Geographic
$16.46B totalAmericas$5.14B · 31.2%
US$4.76B · 28.9%
Non Us$3.47B · 21.1%
EMEA$1.83B · 11.1%
Asia Pacific$1.26B · 7.6%
Peer comparison
Same SIC group: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Comparing ZIMMER BIOMET HOLDINGS against the 5 most active filers in the same SIC group.
Dividends
$0.96/share trailing 12 months · 0.0% YoY
| Ex-date | Per share |
|---|---|
| Mar 31, 2026 | $0.2400 |
| Dec 30, 2025 | $0.2400 |
| Sep 30, 2025 | $0.2400 |
| Jun 26, 2025 | $0.2400 |
| Mar 31, 2025 | $0.2400 |
| Dec 30, 2024 | $0.2400 |
| Sep 30, 2024 | $0.2400 |
| Jun 26, 2024 | $0.2400 |
| Mar 27, 2024 | $0.2400 |
| Dec 26, 2023 | $0.2400 |
| Sep 28, 2023 | $0.2400 |
| Jun 23, 2023 | $0.2400 |
| Mar 28, 2023 | $0.2400 |
| Dec 23, 2022 | $0.2400 |
| Sep 29, 2022 | $0.2400 |
| Jun 24, 2022 | $0.2400 |
| Mar 28, 2022 | $0.2400 |
| Dec 27, 2021 | $0.2330 |
| Sep 29, 2021 | $0.2330 |
| Jun 25, 2021 | $0.2330 |
| Mar 26, 2021 | $0.2330 |
| Dec 24, 2020 | $0.2330 |
| Sep 29, 2020 | $0.2330 |
| Jun 26, 2020 | $0.2330 |